Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Beam Therapeutics Inc. (NASDAQ: BEAM)
BEAM Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
9.40%
Analyst Rating:
BUY
Analyst Forecast (1yr):
89%
BEAM Stock Analysis
BEAM
PE Ratio:
BEAM
PEG Ratio:
Not Available
BEAM
Forward EPS Growth (12 month):
0.00%
BEAM
PS Ratio:
18.5
BEAM
PSG Ratio:
0.9
BEAM
Forward Revenue Growth (12 month):
20.70%
BEAM Articles
No data was found